HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications

ONCOLOGY

Volumn 11, Issue 3 SUPPL. 2, 1997, Pages 43-48

  Baselga, José ^a   Seidman, Andrew D ^b   Peter Rosen, P ^b   Norton, Larry ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; NONHUMAN;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 0030947407     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Rowinsky EK, Donehower RC: Drug therapy, paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995.
2. Aaronson SA: Growth factors and cancer. Science 254:1146-1153, 1991.
3. Coussens L, Yang-Feng TL, Liao Y-C, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985.
4. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986.
5. Stern DF, Hefferman PA, Weinberg RA: p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity. Mol Cell Biol 6:1729-1740, 1986.
6. Hynes NE, Stern DF: The biology of erB-2/ neu/HER-2 and its role in cancer. Biochemica et Biophysica Acta 1198:165-184, 1994.
7. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707, 1989.
8. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182, 1987.
9. Ravdin PV, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 159:19-27, 1995.
10. HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163, 1987.
11. Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science 1987; 237:178-182.
12. Guy CT, Webster MA, Schaller M, et al: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582, 1992.
13. Gusterson BA, Machin LG, Gullick WJ, et al: Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer 42:842-845, 1988.
14. van de Vijver MJ, Peterse JL, Moot WJ, et al: NEU-protein overexpression in breast cancer - association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer N Engl J Med 319:1239-1245, 1988.
15. Drebin JA, Link VC, Stern DF, et al: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706, 1985.
16. McKenzie SJ, Marks PJ, Lam T, et al: Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4:543-548, 1989.
17. Stancovski I, Hurwitz E, Leitner D, et al: Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc Natl Acad Sci USA 88:8691, 1991.
18. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloro-platinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991.
19. Harwerth IM, Wels W, Schlegel J, et al: Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 68:1140-1145, 1993.
20. HER2 Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989.
21. HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993.
22. Shepard HM, Lewis GD, Sarup JC, et al: Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic (review). J Clin Immunol 11:117-127, 1991.
23. Klijn JGM, Berns EMJJ, Bontenbal M, et al: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19:45-63, 1993.
24. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992.
25. Carlomagno C, Perrone F, Gallo C, et al: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996.
26. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced y the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992.
27. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992.
28. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
29. Seidman AD, Baselga J, Yao T-J, et al: HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer (mbc) (abstract). Proc Am Soc Clin Oncol 15:#80, 1996.
30. WAF1 and p53 requires c-raf-1. Cancer Res 55:4623-4626, 1995.
31. Blagosklonny MV, Schulte T, Nguyen P, et al: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56:1851-1854, 1996.
32. Ding A, Sanchez E, Nathan CF: Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associaled protein kinase. J Immunol 151:5596-5602, 1993.
33. Waskiewicz AJ, Cooper JA: Mitogen and stress response pathways: MAP kinase cascades and phosphatase regualtion in mammals and yeast. Curr Opin Cell Biol 7:798-805, 1995.
34. Fendly BM, Winget M, Hudziak RM, et al: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor to HER2/neu gene product. Cancer Res 50:1550-1558, 1990.
35. Drebin JA, Link VC, Weinberg RA, et al: Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83:9129-9133, 1986.
36. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994.
37. Baselga J, Norton L, Coplan K, et al: Antitumor activity of placitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts (abstract). Proceedings American Association for Cancer Research 35:2262, 1994.
38. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
39. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
40. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloro-platinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991.
41. c-erbB-2 Signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994.
42. Pegram M, Lipton A, Pietras R, et al: Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastasic breast cancer (abstract). Proc Am Soc Clin Oncol 14:124, 1995.
43. Levitzki A, Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-1787, 1995.
44. Osherov N, Gazit A, Gilon C, et al: Selective inhibition of the epidermal growth factor and Her2/neu receptors by tyrphostins. J Biol Chem 268:11134-11142, 1993.
45. Fry DW, Kraker AJ, McMichael A, et al: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093, 1994.
46. Bos M, Mendelsohn J, Kim YM, et al: A tyrosine kinase inhibitor prevents ligand-induced receptor activation and inhibits growth of cancer cell lines expressing the epidermal growth factor receptor (abstract). Proc Am Assoc Cancer Res 37:305, 1996.
47. Zhang L, Hung M-C: Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12:571-576, 1996.